Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K11 | Q16584 | 12/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL977379 | 1.00 | MAP3K11 (0.52) | MAP3K11MEN1KMT2AGSK3BNPC1 | |
| SCHEMBL976663 | 0.78 | FYN (0.52) | CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL976660 | 0.78 | FYN (0.52) | CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL976658 | 0.78 | FYN (0.52) | CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL978088 | 0.78 | FYN (0.52) | CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL976661 | 0.78 | FYN (0.52) | CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL978090 | 0.78 | FYN (0.52) | CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL977456 | 0.77 | MAP3K11 (0.54) | MAP3K11MEN1KMT2AGSK3BNPC1 | |
| SCHEMBL976456 | 0.76 | MAP3K11 (0.54) | MAP3K11MEN1KMT2AGSK3BNPC1 | |
| SCHEMBL977402 | 0.75 | MTOR (0.53) | ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170266192-A1 | METHODS FOR IMPROVING DIAPHRAGM FUNCTION | CYTOKINETICS INC (US) | 2017-09-21 | — | — | US | claimed |
| EP-2069352-B9 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS INC (US) | 2017-03-15 | — | — | EP | claimed |
| EP-2995619-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS COMPRISING IMIDAZOPYRIMIDINES | Cytokinetics, Inc. (US) | 2016-03-16 | — | — | EP | claimed |
| EP-2583970-B1 | Certain chemical entities, compositions and methods comprising imidazopyrimidines | CYTOKINETICS INC (US) | 2015-10-14 | — | — | EP | claimed |
| US-20150065525-A1 | METHODS FOR IMPROVING DIAPHRAGM FUNCTION | CYTOKINETICS, INC. | 2015-03-05 | — | — | US | claimed |
| EP-2834269-A1 | METHODS FOR IMPROVING DIAPHRAGM FUNCTION | Cytokinetics, Inc. (US) | 2015-02-11 | — | — | EP | claimed |
| EP-2666777-A1 | Certain chemical entities having an imidazo<4,5-b>pyrazin-2(3H)-one core, compositions and methods | Cytokinetics, Inc. (US) | 2013-11-27 | — | — | EP | claimed |
| WO-2013151938-A1 | METHODS FOR IMPROVING DIAPHRAGM FUNCTION | CYTOKINETICS, INC. (US) | 2013-10-10 | — | — | WO | claimed |
| EP-2069352-B1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS INC (US) | 2013-10-09 | — | — | EP | claimed |
| EP-2583970-A1 | Certain chemical entities, compositions and methods comprising imidazopyrimidines | Cytokinetics, Inc. (US) | 2013-04-24 | — | — | EP | claimed |
| US-8299248-B2 | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use | CYTOKINETICS, INCORPORATED (US) | 2012-10-30 | — | — | US | claimed |
| US-8293761-B2 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. (US) | 2012-10-23 | — | — | US | claimed |
| US-8227603-B2 | Modulating skeletal muscle | CYTOKINETICS, INC. (US) | 2012-07-24 | — | — | US | claimed |
| US-20110014212-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INCORPORATED | 2011-01-20 | — | — | US | claimed |
| US-20100210645-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC. | 2010-08-19 | — | — | US | claimed |
| US-7598248-B2 | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2009-10-06 | — | — | US | claimed |
| EP-2069352-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2009-06-17 | — | — | EP | claimed |
| US-20080146561-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2008-06-19 | — | — | US | claimed |
| WO-2008016669-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-02-07 | — | — | WO | claimed |
| US-10766899-B2 | Methods for preparing substituted imidazo[4,5-b]pyrazines | CYTOKINETICS, INCORPORATED (US) | 2020-09-08 | — | — | US | disclosed |
| EP-2995619-B1 | CERTAIN CHEMICAL ENTITIES COMPRISING IMIDAZOPYRIMIDINES, COMPOSITIONS AND METHODS | CYTOKINETICS INC (US) | 2019-09-25 | — | — | EP | disclosed |
| US-20190167676-A1 | METHODS FOR IMPROVING RESISTANCE TO SKELETAL MUSCLE FATIGUE | CYTOKINETICS, INC. | 2019-06-06 | — | — | US | disclosed |
| US-20170266192-A1 | METHODS FOR IMPROVING DIAPHRAGM FUNCTION | CYTOKINETICS INC (US) | 2017-09-21 | — | — | US | disclosed |
| EP-2069352-B9 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS INC (US) | 2017-03-15 | — | — | EP | disclosed |
| EP-2995619-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS COMPRISING IMIDAZOPYRIMIDINES | Cytokinetics, Inc. (US) | 2016-03-16 | — | — | EP | disclosed |
| EP-2583970-B1 | Certain chemical entities, compositions and methods comprising imidazopyrimidines | CYTOKINETICS INC (US) | 2015-10-14 | — | — | EP | disclosed |
| US-20150250784-A1 | METHODS FOR IMPROVING RESISTANCE TO SKELETAL MUSCLE FATIGUE | CYTOKINETICS, INC. | 2015-09-10 | — | — | US | disclosed |
| US-20150065525-A1 | METHODS FOR IMPROVING DIAPHRAGM FUNCTION | CYTOKINETICS, INC. | 2015-03-05 | — | — | US | disclosed |
| EP-2836590-A2 | METHODS FOR IMPROVING RESISTANCE TO SKELETAL MUSCLE FATIGUE | Cytokinetics, Incorporated (US) | 2015-02-18 | — | — | EP | disclosed |
| EP-2834269-A1 | METHODS FOR IMPROVING DIAPHRAGM FUNCTION | Cytokinetics, Inc. (US) | 2015-02-11 | — | — | EP | disclosed |
| US-20140303366-A1 | Certain 1H-Imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-Imidazo[4,5-b]pyrazin-2-ols and Methods for Their Use | CYTOKINETICS, INCORPORATED | 2014-10-09 | — | — | US | disclosed |
| US-8716291-B2 | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use | CYTOKINETICS, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| EP-2666777-A1 | Certain chemical entities having an imidazo<4,5-b>pyrazin-2(3H)-one core, compositions and methods | Cytokinetics, Inc. (US) | 2013-11-27 | — | — | EP | disclosed |
| WO-2013155262-A2 | METHODS FOR IMPROVING RESISTANCE TO SKELETAL MUSCLE FATIGUE | CYTOKINETICS, INC (US) | 2013-10-17 | — | — | WO | disclosed |
| WO-2013151938-A1 | METHODS FOR IMPROVING DIAPHRAGM FUNCTION | CYTOKINETICS, INC. (US) | 2013-10-10 | — | — | WO | disclosed |
| EP-2069352-B1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS INC (US) | 2013-10-09 | — | — | EP | disclosed |
| EP-2583970-A1 | Certain chemical entities, compositions and methods comprising imidazopyrimidines | Cytokinetics, Inc. (US) | 2013-04-24 | — | — | EP | disclosed |
| US-20130053389-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. | 2013-02-28 | — | — | US | disclosed |
| US-8299248-B2 | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use | CYTOKINETICS, INCORPORATED (US) | 2012-10-30 | — | — | US | disclosed |
| US-8293761-B2 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-7956056-B2 | Certain 1H-imidazo[4,5-B]pyrazin-2(3H)-ones and 1H-imidazo[4,5-B]pyrazin-2-ols, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2011-06-07 | — | — | US | disclosed |
| US-20110014212-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INCORPORATED | 2011-01-20 | — | — | US | disclosed |
| US-20100210645-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC. | 2010-08-19 | — | — | US | disclosed |
| US-20100093741-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. | 2010-04-15 | — | — | US | disclosed |
| US-7598248-B2 | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| EP-2069352-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20080146561-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2008-06-19 | — | — | US | disclosed |
| WO-2008016669-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
| WO-2008016669-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210645-A1 | Certain Chemical Entities, Compositions and Methods | TNNC1, TNNI3, TNNT2 | MAP3K11 1398/4885MEN1 3402/4885KMT2A 4284/4885 |
| US-20130053389-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | TNNI3, TNNT2, TNNC1 | MAP3K11 1263/4885MEN1 698/4885KMT2A 2568/4885 |
| US-20170266192-A1 | METHODS FOR IMPROVING DIAPHRAGM FUNCTION | TNNC1, TNNI3, DIAPH1 | MAP3K11 3679/4885MEN1 4391/4885KMT2A 3384/4885 |
| US-20150065525-A1 | METHODS FOR IMPROVING DIAPHRAGM FUNCTION | TNNC1, TNNI3, TNNT2 | MAP3K11 3980/4885MEN1 4310/4885KMT2A 3890/4885 |
| US-20080146561-A1 | Certain chemical entities, compositions and methods | TNNC1, TNNI3, TNNT2 | MAP3K11 1398/4885MEN1 3402/4885KMT2A 4284/4885 |
| US-10766899-B2 | Methods for preparing substituted imidazo[4,5-b]pyrazines | CYP4B1, CYP3A5, CYP4F12 | MAP3K11 1239/4885MEN1 768/4885KMT2A 2533/4885 |
| US-20140303366-A1 | Certain 1H-Imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-Imidazo[4,5-b]pyrazin-2-ols and Methods for Their Use | TNNI3, TNNT2, TNNC1 | MAP3K11 2147/4885MEN1 2157/4885KMT2A 2911/4885 |
| US-20190167676-A1 | METHODS FOR IMPROVING RESISTANCE TO SKELETAL MUSCLE FATIGUE | TNNC1, TNNI3, TNNT2 | MAP3K11 2088/4885MEN1 4804/4885KMT2A 4461/4885 |
| US-20100093741-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | TNNC1, TNNI3, TNNT2 | MAP3K11 1398/4885MEN1 3402/4885KMT2A 4284/4885 |
| US-20110014212-A1 | Certain Chemical Entities, Compositions and Methods | TNNI3, TNNT2, TNNC1 | MAP3K11 1263/4885MEN1 698/4885KMT2A 2568/4885 |
| US-20150250784-A1 | METHODS FOR IMPROVING RESISTANCE TO SKELETAL MUSCLE FATIGUE | TNNC1, TNNI3, TNNT2 | MAP3K11 2088/4885MEN1 4804/4885KMT2A 4461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.